Abstract

Justiciaflava (Acanthaceae) is utilized in folk medicine for treating malaria, inflammatory conditions, and respiratory infections. In this study, the antiplasmodial and anti-inflammatory activities of the 70% hydroalcoholic leaf extract of J. flava (JFE) were investigated. The antiplasmodial activity was assessed by the suppressive test and Rane’s curative test. The carrageenan-induced paw oedema assay in chicks was used to assess the anti-inflammatory activity. In Rane’s curative test, JFE significantly suppressed the parasitaemia level ( < 0.0001) by 56.85%, 63.85%, and 77.85% at 30, 100, and 300 mg·kg−1, respectively. The highest suppression of parasitaemia in the suppressive test was 51.31% at 300 mg·kg−1. The extract prolonged the survival time of infected mice significantly and prevented weight loss and hypothermia which are cardinal signs of P. berghei-induced infection. JFE inhibited foot oedema in chicks with a maximum percentage inhibition of 54.00 ± 5.20%. Pharmacognostic characterization of J. flava revealed it to have simple, petiolate, oppositely arranged leaves which are broadly lanceolate in shape with entire to slightly crenate margins. Microscopy of the leaf showed wavy-walled epidermal cells, diallelocytic stomata, abundant clothing and secretory trichomes, pitted vessels, collateral conjoint vascular bundles, cystoliths, and prismatic calcium oxalate crystals. Flavonoids, tannins, phytosterols, triterpenoids, coumarins, alkaloids, and saponins were detected in the plant. This study has provided important parameters for the correct identification of J. flava and given the scientific credence to its antimalarial and anti-inflammatory effects in traditional medicine. J. flava is a potential source of new antimalarial and anti-inflammatory compounds.

1. Introduction

The genus Justicia, with over 600 species of scandent perennial herbs and shrubs, represents the largest genus in the family Acanthaceae [1]. Its species are usually found in warm and temperate regions of the world including Africa, Asia, and America. Justicia spp. are recognized for numerous ethnomedicinal applications including their use for treating inflammatory diseases, diabetes, fever, malaria, asthma attacks, respiratory tract infections, bacterial infections, and sexually transmitted diseases [1, 2]. Justicia species have demonstrated significant bioactivities making them important sources of therapeutic agents. These include antiviral [3], antimicrobial [4], antioxidant [5], anticancer [6], anti-inflammatory [7], hepatoprotective [8], antidiabetes [9], anticonvulsant, sedative, and anxiolytic [10] properties. The antimalarial activity of several Justicia species has also been well reported [11]. J. betonica, J. carnea, J. adhatoda, J. schimperiana, and J. flava are species used to treat malaria in Uganda, Cameroon, Ethiopia, Kenya, Nigeria, and Ghana [1114]. In a previous study, the leaves of J. schimperiana demonstrated significant prophylactic and curative effects against Plasmodium infection in mice [15]. The leaves of J. carnea also demonstrated significant in vitro antiplasmodial effects against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum strains [11]. J. carnea leaf extract was also found to exert a modulatory effect on the antiplasmodial activity of chloroquine and artesunate [16]. In another study, extracts of the leaves of J. betonica and J. adhatoda caused a significant suppression of P. falciparum schizont growth in an in vitro assay [17, 18].

Justicia flava is one of the most widespread species of the genus in West Africa [19]. It is a perennial herb or shrublet, which grows up to about 450 mm high, and is characterized by bright yellow terminal inflorescences, embedded in leaf-like bracts. The plant is called “afama” or “ntumunum” in the local Ghanaian Akan language and is used to treat malaria, fever, yaws, dysentery, and diarrhoea [20, 21]. Other ethnomedicinal uses of the plant across the African continent include vermifuge, emetic, analgesic, wound healing, against respiratory tract infections, pulmonary diseases, menstrual disorders, miscarriages, oedema, gout, paralysis, epilepsy, and convulsions [2123]. Though several medicinal uses have been reported for J. flava in traditional medicine, only few scientific investigations have been carried out to substantiate the biological effects of the plant. These include its wound healing [20], antioxidant [24], antimicrobial [20], tocolytic [22], analgesic, and antipyretic [23] activities. J. flava is well known for its use in relieving fever and joint aches associated with malaria. Meanwhile, there is currently no scientific report which gives credence to its antimalarial effect. In continuing our studies on the potential of the Ghanaian flora as valuable sources of bioactive agents, this study reports the antimalarial and anti-inflammatory effects of the leaves of J. flava. This is to give scientific credence to its use in folk medicine for the treatment of malaria and inflammatory conditions. Important macromorphological and micromorphological features of J. flava are also described.

2. Materials and Methods

2.1. Plant Material Collection and Extraction

J. flava leaves were harvested from Abetifi in the eastern part of Ghana in March 2022. Sample authentication was done by Dr. George Henry Sam, Herbal Medicine Department, KNUST, and a specimen with voucher number KNUST/HMI/2014/L084 was deposited at the herbarium. The leaf samples were carefully washed with clean tap water, air-dried under shade for a week, and ground into powder using a mechanical grinder. Extraction was carried out by cold macerating approximately 1000 g of the powdered leaves in 70% ethanol for 72 h. The filtrate was reduced to a green syrupy extract on a rotary evaporator and further dried in an oven (40°C). A semisolid dried extract (JFE) weighing ∼87 g (percentage yield = 8.7%w/w) was obtained and stored in an airtight container till needed for use.

2.2. Pharmacognostic Studies
2.2.1. Macroscopic and Microscopic Assessment

The leaves of J. flava were examined for organoleptic characteristics including taste, colour, odour, and texture. Macroscopic features of the leaf such as the leaf type, leaf arrangement, and lamina characteristics were noted. Microscopic assessment was carried out with the aid of a light microscope (DM-700) with a camera attached. Free-hand sections of the cleared leaf lamina, midrib, and petiole were observed under the microscope, and photomicrographs of cell types and cell inclusions were taken at ×10 and ×40 magnifications. The epidermal number, stomatal number and index, palisade ratio, veinlet termination, and vein-islet numbers were calculated as previously described [25].

2.3. Phytochemical Screening

Major classes of secondary metabolites were screened for, following previously described protocols [26].

2.4. Biological Activity Screening
2.4.1. Animals

Cockerels (Gallus gallus, strain Shaver 579) were obtained from Akropong farms (Kumasi, Ghana) one-day after hatch and transferred to the vivarium of the Department of Pharmacology, KNUST, Kumasi. The chicks were housed in groups of 12 chicks per cage in stainless steel cages (34 × 57 × 40 cm2). They were maintained at room temperature of 29°C under overhead incandescent illumination granting a 12 h light-dark cycle. The chicks were fed with chick mash (GAFCO, Tema, Ghana) and water. The chicks were used for experiments at 7 days of age.

Swiss albino mice (16–28 g) and chloroquine-sensitive Plasmodium berghei (ANKA strain)-infected donor albino rats were obtained from the Animal Facility Centre (AFC) of the Noguchi Memorial Institute for Medical Research (NMIMR), Legon, Accra, Ghana. The animals were kept in a vivarium at the Pharmacology Department, KNUST, where all experiments were carried out. They were housed in cages with wood shaven as bedding under a 12-hour natural light-dark cycle. The temperature of the lab was maintained at 27 ± 1°C with a relative humidity of 60–70%. The animals were fed with rodent feed and supplied with water ad libitum. All procedures employed were permitted by the Animal Research Ethics Committee (AREC) of KNUST. All experimental animals were handled according to the instructions given by the National Institute of Health Guidelines for the Care and Use of Laboratory Animals (2011).

2.4.2. Animal Grouping and Dosing

For all in vivo assays, animals were put into five groups consisting of five mice each. These included three test groups which received doses of the test extract orally, the vehicle-treated group, which was given normal saline, and the positive control group which was administered the standard drug.

2.4.3. Acute Oral Toxicity Assay

The acute oral toxicity assay of JFE extract was performed according to the fixed dose method as given by the Guideline 420 of the Organization of Economic Cooperation and Development (OECD) [27]. Accordingly, Swiss albino mice, either male or female, were selected randomly and placed in two groups of five animals each and fasted overnight. Group 1 received a dose of JFE 5000 mg·kg−1 bodyweight (solubilized in distilled water), and group 2 received 0.2 mL of normal saline. The general behaviour/well-being of mice as well as any signs of toxicity (including change in skin colour, salivation, diarrhoea, lacrimation, change in fur, nostril discharge, lethargy, convulsion, tremor, and death) were observed continuously for an hour, then subsequently every 30 min for 4 h, then after 24 h, and daily for the next 14 days. If three or more mice survived, the LD50 was stated to be more than 5000 mg·kg−1.

2.5. In Vivo Antiplasmodial Activity
2.5.1. Inoculation of Parasite

Healthy mice were infected with the Plasmodium parasite by intraperitoneal injection of 0.2 mL of inoculum (infected blood with the parasitaemia level: 1 × 107 parasitized erythrocytes) as described by Baah et al. [28].

2.5.2. The 4-Day Suppressive Test (Prophylactic Assessment)

The method described by Baah et al. [28] was followed in this assay. Briefly, mice infected with the Plasmodium parasite were selected randomly and grouped into five groups (5 mice/group). Three hours after parasite inoculation, the treatment groups received JFE 300, 100, and 30 mg·kg−1·day−1 (p.o); the negative controls received normal saline, 0.2 mL (p.o.); and the positive controls were given artesunate, 4 mg·kg−1·day−1 (i.p.). Treatment of mice was done at the same time each day and continued for the next four days (day 0 to day 3). After treatment on day 3, blood samples were obtained from the tails of mice in all treatment groups for analysis of parasitized RBCs. This was done without euthanizing the animals. Thin blood smears were fixed on glass slides with absolute MeOH, stained permanently with 10% Giemsa solution, and viewed under a light microscope at an objective magnification of ×100. Infected RBCs were counted from 5 randomly selected fields of view, and the percentage parasitaemia was determined as follows:

Percentage parasitaemia suppression was calculated as

Here, A is the average % parasitaemia in the untreated group and B is the average % parasitaemia of the treated groups.

2.5.3. Rane’s Curative Assay

This assay investigated the curative potential of JFE following a previously described method by Baah et al. [28]. Infection of mice was performed as described in Section 2.5.1. Three days after infection, the mice were grouped into five groups (5 mice/group). Groups 1, 2, and 3 (treatment groups) received JFE 30, 100, and 300 mg·kg−1·day−1 (p.o), respectively, group 4 received 0.2 mL of normal saline orally, and group 5 received artesunate, 4 mg·kg−1·day−1 (i.p.). Treatment continued for the next four days (day 3 to day 7). After treatment on day 3 and day 7, blood samples were obtained from the tails of mice in all treatment groups for analysis of parasitized RBCs. Thin blood smears were fixed on glass slides with absolute MeOH, stained permanently with 10% Giemsa solution, and viewed under a light microscope at an objective magnification of ×100. The level of parasitaemia on days 3 and 7 was determined by the formulas in Section 2.5.2.

2.5.4. Monitoring Survival Time

The length of survival time (in days) for each mouse was recorded within a 30-day period of observation in both suppressive and curative assays. The mice were observed from the day of infection to the day of death (i.e., if death occurs). The mean survival time (MST) was then determined by the formula:

2.5.5. Assessment of Body Weight and Body Temperature

The body weights of animals were taken on a digital balance and the rectal temperatures were taken with a digital thermometer. In the suppressive assay, these parameters were recorded on the day of infection (day 0) and after treatment on the 3rd day. In the curative assay, these parameters were taken on the 3rd and 7th days of treatment.

2.6. Carrageenan-Induced Footpad Oedema Assay in Chicks

The anti-inflammatory assay was performed as previously described [29]. Foot pad oedema was induced by injecting the subplantar tissue of the right footpad of chicks with 10 µL of 2% carrageenan solution. Before the induction of oedema, the footpad diameter was measured. Exactly 1 hour after carrageenan injection, the chicks were treated with JFE extract suspended in normal saline at doses of 300, 100, and 30 mg·kg−1 given orally. Diclofenac sodium (10, 30, and 100 mg·kg−1i.p) was given as a reference drug and normal saline (2 mL, p.o.) as the negative control. The diameter of the chick footpad was recorded hourly for 5 hours with the aid of vernier callipers. The raw footpad diameters were used to determine the percentage change in foot pad size as follows:

Here, is the foot pad diameter at time 0 and is the foot pad diameter at time “t.”

2.7. Data Management Analysis

The results of the experiments were analysed using GraphPad Prism (version 8 for windows, San Diego, USA). The data are given as the mean ± standard error mean (SEM). One-way analysis of variance (ANOVA) was used to make comparisons between the untreated and treated groups. Dunnet’s post hoc test was used for multiple comparisons between tests.

3. Results

3.1. Organoleptic and Macromorphological Characteristics

The organoleptic and macromorphological examination of J. flava leaves revealed that J. flava has simple, green, petiolate leaves which are oppositely arranged on the stem (Figures 1(a) and 1(b)). The leaves are lanceolate to broadly lanceolate with entire to slightly crenate margins, arcuate venation, and a slightly rough surface (Figures 1(c) and 1(d)). The plant bears terminal flowers subtended in leafy bracts. The powdered leaf sample has a bitter taste and nonspecific odour. A summary of the organoleptic and macromorphological features of J. flava leaf is provided in Table 1.

3.2. Microscopic Characteristics of J. flava Leaf
3.2.1. Leaf Lamina

Microscopy of the cleared leaf laminar displayed wavy-walled anticlinal epidermal cells on both surfaces. Diacytic stomata, i.e., stomatal pores with two subsidiary cells positioned perpendicular to the guard cells having common walls obliquely positions in a C-shape (diallelocytic stomata), were abundant. Glandular trichomes with a multicellular head and a unicellular stalk were also observed. Vein-islets (Vi) and veinlet terminations (Vt) were observed (Figures 2(a)–2(d)).

3.2.2. Transverse Section (T/S) of the Midrib and Petiole

Microscopy of the T/S of the midrib showed a planoconvex-shaped midrib with one layer of polygonal-shaped epidermal cells externally covered by a thin cuticle. Several uniseriate multicellular clothing trichomes were found on the upper epidermal layer and few on the lower epidermis. About 4-5 layers of closely packed collenchyma were observed above the lower epidermis and below the upper epidermal layer. Several parenchyma cells filled the midregion, at the centre of which collateral conjoint vascular bundles in the open arch were located. Two smaller meristeles were observed in the upper region placed beneath the palisades on either side, slightly above the central meristele.

The T/S of the petiole displayed a circular-shaped petiole with undulating outline having abundant multicellular uniseriate nonglandular (covering) trichomes as well as glandular trichomes on the outer surface. A thin layer of cuticle, followed by one layer of polygonal epidermal cells and collenchyma, was observed. Parenchyma filled the core. Vascular bundles were present as meristeles, radially arranged along the periphery of the petiole. Xylem was located toward the interior and phloem to the exterior (Figures 2(e)–2(j)).

Microscopy of the leaf powder displayed prismatic calcium oxalate crystals, pitted xylem vessels, and lignified fibres (Figure 3). Leaf surface constants are presented in Table 2.

3.3. Phytochemical Screening

Major classes of plant secondary metabolites including tannins, glycosides, triterpenoids, phytosterols, alkaloids, coumarins, and flavonoids were identified in the leaves of J. flava (Table 3).

3.4. Acute Toxicity

The hydroalcoholic leaf extract of J. flava at an oral dose of 5000 mg·kg−1 did not result in any behavioural, neurological, or physical changes such as staggering gait, anxiety, sedation, agitation, emesis, excessive salivation, straub tail, or diarrhoea in mice during 24 hours of monitoring and for 14 days after treatment. No death was recorded. The LD50 was estimated to be more than 5000 mg kg−1.

3.5. In Vivo Antiplasmodial Activity of J. flava Leaf Extract
3.5.1. Four-Day Suppressive Test

The suppressive test was employed to assess the ability of J. flava leaf extract (JFE) to suppress parasitaemia. JFE demonstrated a significant ( < 0.0001) dose-dependent inhibition of parasite growth at the doses tested when compared to the untreated group. The most remarkable parasitaemia suppression (51.31%) was demonstrated by JFE 300 mg·kg−1. The extract also significantly prolonged the mean survival rate of mice. JFE 300 mg·kg−1 gave the longest survival time of 23.85 (±1.50) days. The positive control, artesunate, however, produced a higher suppression of parasitaemia (92.14%) than all doses of the leaf extract. The results are presented in Table 4.

3.5.2. Effect of J. flava on Body Temperature and Body Weight in the Suppressive Test

All treated and untreated mice infected with P. berghei experienced a decrease in body temperature from the day of infection till treatment was completed. Nevertheless, the change in rectal temperature recorded in infected mice in the negative control group was greater than that of the JFE and artesunate-treated groups (Table 5). Treatment with JFE also prevented a decline in the body weight of P. berghei-infected mice and rather caused a slight increase in weight of mice. Contrary to this, the normal saline-treated group experienced a decrease in weight after the induction of parasitaemia (Figure 4).

3.5.3. Rane’s (Curative) Test

After an established infection on day 3, all doses of JFE extract administered (30, 100, and 300 mg·kg−1) caused a remarkable decrease in the parasitaemia level by day 7. The effect was significant and dependent on the dose administered ( < 0.0001). The highest dose of JFE, 300 mg·kg−1·day−1, remarkably suppressed parasitaemia by 77.85% by day 7. Artesunate (4 mg·kg−1·day−1) exhibited a higher curative ability with a percentage parasitaemia suppression of 92.48% on day 7. The duration of survival of infected mice treated with JFE and artesunate was also substantially prolonged at all doses contrary to the untreated group (Table 6).

3.5.4. Effect of J. flava on Body Weight and Body Temperature in the Curative Test

All doses of J. flava averted loss of weight in infected mice between days 3 and 7 ( < 0.0001). The saline-treated group, however, experienced a substantial loss in weight by day 7 (Figure 5). Treatment with artesunate also prevented weight loss in infected mice. A slight reduction in temperature was observed for all P. berghei-infected mice from the 3rd to the 7th day (Table 7). The change in body temperature for JFE- and artesunate-treated mice was, however, less pronounced compared to the temperature change in the negative control group.

3.6. Effect of J. flava Leaf Extract on Carrageenan-Induced Footpad Oedema

Subcutaneous injection of 2% carrageenan into the chicks’ footpads caused moderate acute inflammation observed as foot oedema. Figures 6(a) and 6(c) represent the time course curves, showing the progression of inflammation in treated and untreated groups, observed over a 6 h period. Figures 6(b) and 6(d) illustrate the total calculated area under the curve for each treatment group, which depicts the total foot oedema that occurred over the 6 h period of the experiment. For the treated groups, i.e., JFE- and diclofenac-treated groups, an increase in oedema was produced between the 1st and 2nd hour after which a sharp decrease in foot pad volume was recorded from the 3rd to the 6th hour. The percentage footpad oedema reduction in chicks treated with JFE was dependent on the dose-dependent and significant ( < 0.0001) when compared to the negative control group. The most remarkable inhibition of oedema was 54.04 ± 2.52%, produced by JFE 300 mg·kg−1 (Table 8). The reference drug, diclofenac, also significantly ( < 0.0001) reduced oedema by 73.88 ± 5.33% dose at 100 mg·kg−1. In the negative control group, however, footpad oedema heightened between the 2nd and 3rd hour and slightly decreased from the 4th hour with substantial oedema present even at the 6th hour.

4. Discussion

In this study, the antiplasmodial and anti-inflammatory activities of the 70% hydroalcoholic extract of J. flava leaves were studied. The LD50 of J. flava leaf extract (JFE) was determined to be more than 5000 mg·kg−1 based on the results of the acute oral toxicity test. This report is congruent with the report by Bafor et al. who also reported an LD50 above 5000 mg·kg−1 for J. flava leaf extract [30].

The antiplasmodial activity of JFE was investigated by the suppressive and curative tests [31]. In both assays, the antiplasmodial effect is based on the percentage suppression of parasitaemia and the average survival period of infected mice in the treated group relative to the untreated group. J. flava leaf extract demonstrated the potential to reduce parasitaemia in both early (∼17–52%) and late or established malaria infection (∼57–71%). The extract demonstrated a better curative ability than suppression, suggesting that the extract may be a better option for treating an established malaria infection than in prophylaxis. Deharo et al. classified in vivo antiplasmodial activity of extracts as being very good, good, or moderate if an extract caused parasitaemia suppression of greater than 50% at a dose of 100, 250, and 500 mg·kg−1·day−1, respectively [32]. Based on this criterion, J. flava leaf extract can be said to have a very good antiplasmodial activity. Moreover, the extract significantly extended the survival period of mice affirming the overall reduction of parasitaemia [33]. Treatment with JFE also averted significant weight loss and hypothermia in Plasmodium-infected animals. The results obtained implied that J. flava leaf extract has the ability to suppress parasitaemia and attenuate the pathological events associated with P. berghei malaria infection.

Lignans are among plant compounds reported to show significant antimalarial activity against P. falciparum and P. berghei [34, 35]. From the leaves of J. flava, the lignans (+) isolariciresinol (1), helioxanthin (2), justicinol (3), prostalidin D (4), 9′-demethylsecolintetralin (5), and dimethylsecoisolariciresinol (6) were previously isolated [22, 36]. Pyrroloquinazoline alkaloids, vasicinol (7) and vasicinone (8), and the pyrrolidine alkaloid, hypercratine (9), have also been reported from J. flava leaves (Figure 7) [22]. In a previous study, vasicinone and vasicine, from J. adhatoda, elicited excellent antiplasmodial activity against P. falciparum [18]. These phytoconstituents may contribute to the observed antimalarial activity of J. flava in this study.

The anti-inflammatory activity of J. flava leaves was evaluated by the carrageenan-induced footpad oedema assay, which is a suitable experimental model for inflammation using chicks or rodents [37]. The inflammatory response elicited by carrageen follows a biphasic phenomenon: first, the production of serotonin, histamine, and bradykinins within the first 2 hours and a latter phase (3–6 h) depicted by the production of prostaglandins and activation of cyclooxygenase-2 (COX-2) [38]. From the experiment, JFE reduced chick foot pad oedema from the 3rd to the 5th hour of the experiment, implying that the extract may be active in the 2nd phase of inflammation. In a previous study, extracts from J. flava leaves inhibited 5-lipooxygenase (5-LOX), the enzyme responsible for the production of leukotrienes from arachidonic acid [24]. Lignans, coumarins, flavonoids, phytosterols, glycosides, and triterpenoids previously isolated from several Justicia species have shown promising anti-inflammatory activity in both in vitro and in vivo models [7, 3942]. Some mechanisms of action suggested for the anti-inflammatory effect of Justicia species include the downregulation of COX-2 and intracellular nitric oxide (iNOS) through the suppression of the NF-κB signalling pathway [43], inhibition of the synthesis, or action of tumor necrosis factor-alpha (TNF-α) and cytokine interleukin-1β (IL-β) [44, 45].

From the pharmacognostic investigation of J. flava, diacytic stomata, wavy-walled epidermal cells, cylindrical cystoliths, prismatic calcium oxalate crystals, conjoint collateral open vascular bundles, and abundant clothing trichomes were consistent generic features previously observed in most Justicia species [4648]. Only pitted vessels were observed in J. flava leaf powder distinguishing this species feature from J. secunda [47], J. adhatoda [49], and J. picta [50] which were reported to have spiral xylem vessels.

5. Conclusion

The antiplasmodial and anti-inflammatory effects of the leaves of Justicia flava were verified in this study. The reduction in parasitaemia coupled with the remarkable weight recovery and prolongation of mice survival period approves the folkloric use of J. flava for the treatment of malaria. Furthermore, the attenuation of inflammatory response recorded as a decrease in chick foot pad oedema justifies the use of the plant in inflammatory conditions. This finding also points to J. flava as a promising source of bioactive antimalarial and anti-inflammatory constituents. The diagnostic pharmacognostic characteristics obtained for the leaves of J. flava are important for the correct identification of the plant. This study highlights the significance of bridging traditional knowledge with modern scientific exploration for the improvement of health and well-being.

Data Availability

The raw data/results from experiments used to arrive at the findings of this study are available from the corresponding author upon request. Previous reports that were used to support this study are cited at relevant places within the text as references.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We appreciate the support of Mr. Clifford Asare for his assistance in plant collection and technicians of the Department of Pharmacognosy and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, KNUST, Kumasi.